IBI355

🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

Business news, market intelligence, and global industry analysis.

The Latest

PMV’s $79.4m cash pile now hinges on rezatapopt’s 2027 ovarian cancer FDA bid

NFI Group’s backlog shrank 10.6% as earnings surged. How can both be true?

Frontera Energy’s post-divestment strategy is shifting toward infrastructure growth, with Puerto Bahía, its ODL pipeline stake and a planned LNG regasification project expected to drive future cash flow after the company returned C$590 million to shareholders. Representative image.

Frontera Energy (TSX: FEC) Q2 puts early-2027 LNG launch in focus

Shell’s Wild Coast offshore exploration plans have suffered a major setback after South Africa’s Constitutional Court blocked the disputed exploration right, sharpening scrutiny of how the country balances energy investment with environmental safeguards and community consultation. Representative image.

Shell plc (LSE: SHEL) blocked from Wild Coast exploration as South Africa faces investment test

Biotech laboratory image illustrating Spero Therapeutics’ shift from Utebzi antibiotic approval to a royalty-funded SP001 immunology strategy. Representative image.

Spero Therapeutics (Nasdaq: SPRO) pivots to immunology after Utebzi approval and $105m financing

Spero Therapeutics uses Utebzi royalties to fund an Innovent immunology pivot. Read how SPRO’s cash runway, CD40L bet and stock discount fit together.

μFR system
αvβ6-integrin
α4β7 integrin
Zywie Ventures
ZYUS Life Sciences
Zyrtec
Zyprexa Zydis
Zynyz
ZYNRELEF
Zynga

August 13, 2026